Upstream Bio补办敲钟仪式：市值12亿美元 OrbiMed是大股东

雷递网10-27

雷递网雷建平 10月27日临床阶段生物技术公司Upstream Bio（股票代码为：“UPB”）日前补办纳斯达克敲钟上市。Upstream Bio发行价17美元，发行1500万股，募资总额为2.55亿美元。Upstream Bio首日开盘价21.5美元，较发行价上涨26%；收盘价为22美元，较发行价上涨29.41%；以首日收盘价计算，公司市值10.75亿美元。截至今日收盘，Upstream ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2478718663?lang=zh_CN&edition=full","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20241027/6386562002026915372833937.png","is_english":false,"pubTime":"2024-10-27 10:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2478718663","market":"hk","top_or_hot":-1,"title":"Upstream Bio补办敲钟仪式：市值12亿美元 OrbiMed是大股东","media":"雷递网","content":"<div>\n<p>雷递网 雷建平 10月27日临床阶段生物技术公司Upstream Bio（股票代码为：“UPB”）日前补办纳斯达克敲钟上市。Upstream Bio发行价17美元，发行1500万股，募资总额为2.55亿美元。Upstream Bio首日开盘价21.5美元，较发行价上涨26%；收盘价为22美元，较发行价上涨29.41%；以首日收盘价计算，公司市值10.75亿美元。截至今日收盘，Upstream ...</p>\n\n<a href=\"https://www.leinews.com/n28046/detail.html\">网页链接</a>\n\n</div>\n","source":"leinews_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Upstream Bio补办敲钟仪式：市值12亿美元 OrbiMed是大股东</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpstream Bio补办敲钟仪式：市值12亿美元 OrbiMed是大股东\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-27 10:00 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.leinews.com/n28046/detail.html><strong>雷递网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>雷递网 雷建平 10月27日临床阶段生物技术公司Upstream Bio（股票代码为：“UPB”）日前补办纳斯达克敲钟上市。Upstream Bio发行价17美元，发行1500万股，募资总额为2.55亿美元。Upstream Bio首日开盘价21.5美元，较发行价上涨26%；收盘价为22美元，较发行价上涨29.41%；以首日收盘价计算，公司市值10.75亿美元。截至今日收盘，Upstream ...</p>\n\n<a href=\"https://www.leinews.com/n28046/detail.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TSLP","symbol_name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","start_time":0,"source_url":"https://www.leinews.com/n28046/detail.html","article_id":"2478718663","we_media_id":null,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20241027/6386562002026915372833937.png"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2478718663","pubTimestamp":1729994427,"columns":[],"sourceInfo":{"source_id":"leinews_highlight","name":"雷帝触网"},"weMediaInfo":null,"summary":"临床阶段生物技术公司Upstream Bio（股票代码为：“UPB”）日前补办纳斯达克敲钟上市，募资总额为2.55亿美元。截至今日收盘，Upstream Bio股价为25.06美元，市值为12.24亿美元。","collect":0,"end_time":0,"defaultTopTitle":"leinews.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"TSLP":"Kurv Yield Premium Strategy Tesla (TSLA) ETF"},"translate_title":"Upstream Bio reissues bell ringing ceremony: OrbiMed is a major shareholder with a market value of $1.2 billion","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSLP":1},"content_text":"雷递网 雷建平 10月27日临床阶段生物技术公司Upstream Bio（股票代码为：“UPB”）日前补办纳斯达克敲钟上市。Upstream Bio发行价17美元，发行1500万股，募资总额为2.55亿美元。Upstream Bio首日开盘价21.5美元，较发行价上涨26%；收盘价为22美元，较发行价上涨29.41%；以首日收盘价计算，公司市值10.75亿美元。截至今日收盘，Upstream Bio股价为25.06美元，市值为12.24亿美元。暂无营收 半年净亏2557万美元Upstream Bio正在开发verekitug，这是目前唯一已知的针对胸腺基质淋巴细胞生成素 (TSLP) 受体的拮抗剂。Upstream Bio已将这种强效单克隆抗体推进到单独的 2 期试验，用于治疗严重哮喘和伴有鼻息肉的慢性鼻窦炎 (CRSwNP)，并计划启动慢性阻塞性肺病 (COPD) 的开发。UPB-101是一种新型重组全人免疫球蛋白G1（IgG1）单克隆抗体（mAb），与人胸腺基质淋巴细胞生成素（TSLP）受体（TSLPR）结合以抑制信号传导。UPB-101旨在解决过敏性和炎症性疾病，包括哮喘。Upstream Bio目前暂无营收，其2023年、2024年运营亏损分别为4011万美元、2391万美元；净亏损分别为2054万美元、2387万美元。Upstream Bio在2024年上半年运营亏损为3255万美元，上年同期的运营亏损为1640万美元；净亏2557万美元，上年同期的净亏损为560万美元。持有超2亿美元现金及现金等价物2023年6月8日，Upstream Bio宣布完成2亿美元B轮融资，本轮融资由Enavate Sciences和Venrock Healthcare Capital Partners联合领投。截至IPO前，Upstream Bio累计募资4亿美元。截至2024年9月30日，Upstream Bio有约2.211亿美元的现金、现金等价物和短期投资。OrbiMed是大股东IPO后，OrbiMed持股为9.97%，AI Upstream LLC持股为8.84%，Altshuler Shaham Provident Fund and Pension持股为6.95%，Decheng Capital Global Life Sciences Fund IV持股为6.32%，TCG Crossover Fund I持股为5.69%；HBM Healthcare Investments持股为5.56%，Maruho Deutschland GmbH持股为5.37%，Enavate Sciences持股为4.42%，Samsara BioCapital持股为4.23%，Omega Fund VII持股为4.17%；BCLS Fund III Investments、Venrock Healthcare Capital Partners分别持股为3.73%，Upstream Bio前CEO Samantha Truex持股为1.14%，Erez Chimovits, M.B.A., M.Sc.持股为1.99%。———————————————雷递由媒体人雷建平创办，若转载请写明来源。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2478718663"}